Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.

By G. Hudes, M. Carducci, P. Tomczak, J. Dutcher, R. Figlin, A. Kapoor, E. Starosławska, J. Sosman, D. McDermott, I. Bodrogi and 9 more. New England Journal of Medicine, 2007

3,620 citations recorded by the source corpus.

Subfields: Molecular Biology, Physiology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/f583baeee4ac57a35fdd05a935386d94cb445dcb

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. R. Shaw
2. Steve Horvath
3. Charles Swanton
4. Gautam Sethi
5. Carlos L. Arteaga
6. Michael N. Hall
7. Ingrid A. Mayer
8. C. Sawyers

In Physiology

1. Steve Horvath
2. Michael N. Hall
3. R. Shaw
4. Manolis Kellis
5. Jason Ernst

In Pulmonary and Respiratory Medicine

1. Pedro C. Barata
2. Charles Swanton
3. Carlos L. Arteaga
4. Ingrid A. Mayer
5. C. Sawyers
6. B. Rini

Citations in the corpus

• Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. (2009, background): “The most common AE was thrombocytopenia, which also was observed in patients with renal cell carcinoma treated with temsirolimus, although with a lower incidence.(39) Thrombocytopenia is more Table 3.”
• Treatment of renal cell carcinoma: Current status and future directions (2017, background): “Both outcomes were shorter with temsirolimus compared with TKIs, which was investigated mainly in the poor-risk population with expected worse parameters.(82) Despite different mechanisms of action, the toxicity profile (any grade 3 or 4) of these therapies shared some similarities, with fatigue/ast”
• Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2010, background): “Temsirolimus has been tested in a phase III study in poor-risk patients only versus IFN, demonstrating evidence of improved OS in this patient population [46].”
• Rapamycin passes the torch: a new generation of mTOR inhibitors (2011, background): “Patients with renal cell carcinoma who had poor prognosis were found to have longer overall survival and progression-free survival when treated with temsirolimus than when treated with interfero”
• Renal cell carcinoma (2017, background): “Temsirolimus has been tested in a phase III study in poor-risk patients only versus IFN, demonstrating evidence of improved OS in this patient population [46].”
• PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer (2023, background): “The safety profile of everolimus in NET, SEGA, angiomy-olipoma, RCC, and breast cancer patients is acceptable.”